Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

Inclusion Criteria: Patients may be enrolled in the study only if they meet all of the following criteria: * 18 years of age or older * The patient or her authorized representative must sign and date an Ethical Review Board-approved informed consent document. All aspects of the protocol must be explained and written informed consent obtained. * Patients must have histological proof of HSIL (CIN 2/3) disease documented. * Cervical swabs must test positive for HPV (by Hybrid Capture 2). * Patients must have a Hb ≥ 9 g/dl, a peripheral WBC ≥ 3000 mm3 and platelet counts ≥ 100,000 mm3. * Normal hepatic and renal functions - AST and ALT \< 2.5 x ULN and creatinine \< 1.5 x ULN, respectively. * Females of childbearing potential must use one of the following birth control methods during the treatment period and 2 weeks thereafter: oral, implantable, injectable contraceptives; abstinence (celibacy). Contraceptive sponges, IUD, spermicides, sponges, condoms, or partner's vasectomy are not acceptable methods of birth control. Exclusion Criteria: Patients will be excluded from the study for any of the following preexisting reasons: * Patients with LSIL (CIN 1) or invasive squamous cell carcinoma (SCC). * SIL (CIN) involving the endocervix as determined by endocervical curettage, or otherwise not amenable to adequate colposcopic follow-up evaluations, i.e. unsatisfactory colposcopy. * CIN 3 involving more than two cervical quadrants on colposcopy. * Patients treated for cervical SIL within the past year. * Patients with other malignancy (except for non-melanoma skin) within the past 5 years. * Patients with any active infections (including HIV) other than HPV. * Patients with known clinically relevant immunological deficiency. * Concurrent treatment with cytotoxic, radiation, or immuno-stimulative therapy, or with systemic corticosteroids at a dose of \> 5 mg/d of prednisone (or its equivalent). * Participation in another investigational medication trial concurrently or within 30 days, or prior participation in an HPV vaccine trial. Treatment within the last 30 days with a medication that has not received regulatory approval at the time of study entry. * Concomitant use of topical vaginal medications. * Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study. * History of allergy or hypersensitivity to cosmetics, toiletries, or other topical or dermatologic products. * Pregnant or lactating females who are nursing and will not consent to cease nursing. * Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.